Literature DB >> 14677035

Systemic juvenile idiopathic arthritis mimics multicentric Castleman's disease.

Shinya Osone1, Akira Morimoto, Junna Tsutsui, Gen Kano, Shinjiro Todo, Tohru Sugimoto.   

Abstract

An 11-year-old girl presented with fever and a large cervical lymphadenopathy. Indicators of inflammation were remarkable: she had extremely high levels of serum interleukin-6 (IL-6) (398 pg/ml) in addition to hypergammaglobulinemia and hypoalbuminemia. Computed tomography (CT) revealed swollen systemic lymph nodes. Two weeks after the onset of symptoms she developed polyarthralgia. Biopsy of the cervical lymph node revealed massive infiltration of plasma cells without hyaline vascular changes. She was diagnosed with systemic juvenile idiopathic arthritis (JIA). The patient's symptoms and hypercytokinemia disappeared soon after corticosteroid treatment was started. This case demonstrates that overproduction of IL-6 is common to systemic JIA and multicentric Castleman's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14677035     DOI: 10.1007/s10067-003-0797-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

1.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

Authors:  K Yoshizaki; T Matsuda; N Nishimoto; T Kuritani; L Taeho; K Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

Review 2.  The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.

Authors:  W B Bowne; J J Lewis; D A Filippa; R Niesvizky; A D Brooks; M E Burt; M F Brennan
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

3.  Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis.

Authors:  P Pignatti; M Vivarelli; C Meazza; M G Rizzolo; A Martini; F De Benedetti
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

Review 4.  Interleukin-6 in biology and medicine.

Authors:  S Akira; T Taga; T Kishimoto
Journal:  Adv Immunol       Date:  1993       Impact factor: 3.543

5.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

6.  Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

Authors:  N Nishimoto; M Sasai; Y Shima; M Nakagawa; T Matsumoto; T Shirai; T Kishimoto; K Yoshizaki
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

7.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes.

Authors:  H Mangge; H Kenzian; S Gallistl; G Neuwirth; P Liebmann; W Kaulfersch; F Beaufort; W Muntean; K Schauenstein
Journal:  Arthritis Rheum       Date:  1995-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.